Literature DB >> 26297251

The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults.

Jie Feng1, Shuyu Hao2, Changcun Pan3, Yu Wang4, Zhen Wu5, Junting Zhang6, Hai Yan7, Liwei Zhang8, Hong Wan9.   

Abstract

Brainstem and thalamic gliomas are rare, and they are poorly understood in adults. Genetic aberrations that occur in these tumors are still unknown. In this study, we investigated whether thalamic gliomas have different genetic aberrations and clinical outcomes compared with brainstem gliomas in adults. Forty-three glioma samples were selected, including 28 brainstem and 15 thalamic gliomas. The frequency of the K27M mutation in adult midline gliomas was 58.1%. High-grade gliomas in the thalamus were statistically significantly more numerous than brainstem gliomas. Patients with K27M mutant brainstem gliomas had a significantly shorter overall survival than patients with wild-type tumors (P = .020) by Cox regression after adjustment for other independent risk factors. However, there was no statistical tendency toward a poorer overall survival in thalamic gliomas containing the K27M mutation compared with wild-type tumors. The presence of the K27M mutation significantly corresponded with mutations in TP53 in thalamic gliomas. Interestingly, the K27M mutation was mutually exclusive with mutations in IDH1, which was detected only in brainstem gliomas. The microarray data identified 86 differentially expressed genes between brainstem and thalamic gliomas with the K27M mutation. The cyclin-dependent kinase 6 (CDK6) gene, which plays an important role in cancer pathways, was found to be differentially expressed between brainstem and thalamic gliomas with K27M mutations. Although the K27M mutation was frequently observed in adult brainstem and thalamic gliomas, this mutation tended to be associated with a poorer prognosis in brainstem gliomas but not in thalamic gliomas. Brainstem gliomas may present different genetic aberrations from thalamic gliomas. These differences may provide guidance for therapeutic decisions for the treatment of adult brainstem and thalamic gliomas, which may have different molecular targets.
Copyright © 2015. Published by Elsevier Inc.

Entities:  

Keywords:  Adult; Brainstem; Glioma; H3F3A mutation; Thalamus

Mesh:

Substances:

Year:  2015        PMID: 26297251     DOI: 10.1016/j.humpath.2015.07.002

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  31 in total

Review 1.  The clinicopathological and prognostic significance of TP53 alteration in K27M mutated gliomas: an individual-participant data meta-analysis.

Authors:  Chengya Dong; Zhengrong Yuan; Qi Li; Yajie Wang
Journal:  Neurol Sci       Date:  2018-04-12       Impact factor: 3.307

Review 2.  Oncogenic Mechanisms of Histone H3 Mutations.

Authors:  Daniel N Weinberg; C David Allis; Chao Lu
Journal:  Cold Spring Harb Perspect Med       Date:  2017-01-03       Impact factor: 6.915

3.  Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations.

Authors:  David A Solomon; Matthew D Wood; Tarik Tihan; Andrew W Bollen; Nalin Gupta; Joanna J J Phillips; Arie Perry
Journal:  Brain Pathol       Date:  2015-12-14       Impact factor: 6.508

Review 4.  The role of histone modifications and telomere alterations in the pathogenesis of diffuse gliomas in adults and children.

Authors:  Julieann Lee; David A Solomon; Tarik Tihan
Journal:  J Neurooncol       Date:  2017-01-07       Impact factor: 4.130

Review 5.  A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics.

Authors:  Martin J van den Bent; Michael Weller; Patrick Y Wen; Johan M Kros; Ken Aldape; Susan Chang
Journal:  Neuro Oncol       Date:  2017-05-01       Impact factor: 12.300

6.  Adult diffuse midline gliomas: Clinical, radiological, and genetic characteristics.

Authors:  Antonio Dono; Takeshi Takayasu; Leomar Y Ballester; Yoshua Esquenazi
Journal:  J Clin Neurosci       Date:  2020-11-01       Impact factor: 1.961

7.  Bithalamic gliomas may be molecularly distinct from their unilateral high-grade counterparts.

Authors:  Alberto Broniscer; Scott N Hwang; Omar Chamdine; Tong Lin; Stanley Pounds; Arzu Onar-Thomas; Lei Chi; Sheila Shurtleff; Sariah Allen; Amar Gajjar; Paul Northcott; Brent A Orr
Journal:  Brain Pathol       Date:  2017-03-12       Impact factor: 6.508

8.  Surgical treatment and survival outcome of patients with adult thalamic glioma: a single institution experience of 8 years.

Authors:  Xiaodong Niu; Tianwei Wang; Xingwang Zhou; Yuan Yang; Xiang Wang; Haodongfang Zhang; Ni Chen; Qiang Yue; Feng Wang; Yuekang Zhang; Yanhui Liu; Qing Mao
Journal:  J Neurooncol       Date:  2020-03-10       Impact factor: 4.130

9.  Thalamic Glioblastoma: Clinical Presentation, Management Strategies, and Outcomes.

Authors:  Yoshua Esquenazi; Nelson Moussazadeh; Thomas W Link; Koos E Hovinga; Anne S Reiner; Natalie M DiStefano; Cameron Brennan; Philip Gutin; Viviane Tabar
Journal:  Neurosurgery       Date:  2018-07-01       Impact factor: 4.654

10.  Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.

Authors:  Michael Karremann; Gerrit H Gielen; Marion Hoffmann; Maria Wiese; Niclas Colditz; Monika Warmuth-Metz; Brigitte Bison; Alexander Claviez; Dannis G van Vuurden; André O von Bueren; Marco Gessi; Ingrid Kühnle; Volkmar H Hans; Martin Benesch; Dominik Sturm; Rolf-Dieter Kortmann; Andreas Waha; Torsten Pietsch; Christof M Kramm
Journal:  Neuro Oncol       Date:  2018-01-10       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.